UCSF Licenses Heart Gene IP from Celera | GenomeWeb

NEW YORK (GenomeWeb News) – Celera said today that the University of California, San Francisco has licensed the rights to use Celera’s KIF6 gene-related intellectual property to develop an in-house test for cardiovascular risk and statin benefit.

The agreement makes UCSF the first lab in the US besides Celera’s Berkeley HeartLab subsidiary to use the Celera discoveries.

Studies have shown an association between KIF6, which encodes a kinesin-like protein 6, and cardiovascular risk and statin benefit.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.